Avatar for Exogene

Fast discovery of safer cancer immunotherapies

Fast discovery of safer cancer immunotherapies

Immunotherapies leverage our own immune system to fight cancer cells and represent the cutting-edge of cancer therapy, but they can also cause toxic side-effects and patient deaths.

By integrating biophysics and cell biology, Exogene’s proprietary machine learning technology enables fast discovery of safer immunotherapies, at scale.

Data Scientist

Computational Immunologist

CEO at Exogene. Expertise in cancer research. Ex-healthcare consultant at World Health Organization. PhD in Computational Oncology from Oxford University.
CTO at Exogene. PhD in Computer Science. Expert in Machine Learning and Optimisation. Previously European Space Agency, Portent.io, RBS, Black Swan, Vodafone.
Funded over

1 round

Latest round

Pre-Seed (Jan 2020)

Stock option plan

Remote first